All In Biotech

Drug Trial Radar · NCT03358472

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

89

Actual

Start

Dec 1, 2017

Primary completion

Jul 19, 2018

Study completion Oct 30, 2025

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Nov 30, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Conditions

  • Head and Neck Cancer

Interventions

  • PembrolizumabDrug

    Pembrolizumab administered intravenously every 3 weeks.

  • EpacadostatDrug

    Epacadostat administered orally twice daily.

  • CetuximabDrug

    Cetuximab administered intravenously on Cycle 1 Day 1 followed by administration every week.

  • CisplatinDrug

    Cisplatin administered intravenously every 3 weeks for \</= 6 cycles.

  • CarboplatinDrug

    Carboplatin administered intravenously every 3 weeks for \</= 6 cycles.

  • 5-FluorouracilDrug

    5-Fluorouracil administered intravenously every 3 weeks for \</= 6 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) of Pembrolizumab + Epacadostat, Pembrolizumab Monotherapy and the EXTREME RegimenTime frame: Minimum Week 9

Locations

73 sites in 14 countries. Site status is shown where the registry gives one.

  • Pacific Cancer Medical Center

    Anaheim, California

  • UC Davis Comprehensive Cancer Center

    Sacramento, California

  • St. Joseph Heritage Healthcare

    Santa Rosa, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • Northwest Georgia Oncology Centers PC

    Douglasville, Georgia

  • U of Kansas Cancer Center

    Westwood, Kansas

  • Baptist Health

    Louisville, Kentucky

  • St. Vincent Healthcare Cancer Ctr

    Billings, Montana

  • New Mexico Cancer Care Alliance

    Albuquerque, New Mexico

  • Oklahoma Cancer Specialists and Research

    Tulsa, Oklahoma

  • Providence Portland Med Center

    Portland, Oregon

  • Huntsman Cancer Institute Univ of Utah

    Salt Lake City, Utah

  • Viginia Mason Med Ctr

    Seattle, Washington

  • Chris OBrien Lifehouse

    Camperdown, New South Wales, Australia

  • Macquarie University Hospital

    North Ryde, New South Wales, Australia

  • Royal Brisbane & Women s Hospital

    Herston, Queensland, Australia

  • Landeskrankenhaus Salzburg

    Salzburg, Austria

  • Allgemeines Krankenhaus der Stadt Wien

    Vienna, Austria

  • Juravinski Cancer Center Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • CHU de Quebec-Universite Laval-Hotel Dieu de Quebec

    Québec, Quebec, Canada

  • Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz

    Miskolc, Hungary

  • Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet

    Szolnok, Hungary

  • Istituto Europeo di Oncologia

    Milan, Italy

  • IRRCS Instituto Clinico Humanitas

    Rozzano, Italy

  • Hyogo Cancer Center

    Akashi, Japan

  • Kyushu University Hospital

    Fukuoka, Japan

  • Hiroshima University Hospital

    Hiroshima, Japan

  • Hokkaido University Hospital

    Hokkaido, Japan

  • Kobe City Medical Center General Hospital

    Kobe, Japan

  • Saitama Cancer Center

    Saitama, Japan

  • Kindai University Hospital

    Sayama, Japan

  • Shizuoka Cancer Center Hospital and Research Institute

    Shizuoka, Japan

  • The Cancer Institute Hospital of JFCR

    Tokyo, Japan

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan

  • Kanazawa University Hospital

    Kanazawa, Ishikawa-ken, Japan

  • Kanagawa Cancer Center

    Yokohama, Kanagawa, Japan

  • Miyagi Cancer Center

    Natori-shi, Miyagi, Japan

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.